Current File : /var/www/html/digiprint/public/site/go8r5d/cache/637e35651511f09ffde4c606830352f0
a:5:{s:8:"template";s:9437:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Open+Sans%3A300%2C400%2C600%2C700%2C800%7CRoboto%3A100%2C300%2C400%2C500%2C600%2C700%2C900%7CRaleway%3A600%7Citalic&subset=latin%2Clatin-ext" id="quality-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css"> html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background:0 0}a:active,a:hover{outline:0}@media print{*{color:#000!important;text-shadow:none!important;background:0 0!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}a[href^="#"]:after{content:""}p{orphans:3;widows:3}.navbar{display:none}}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:62.5%;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#428bca;text-decoration:none}a:focus,a:hover{color:#2a6496;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}ul{margin-top:0;margin-bottom:10px}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-md-12{position:relative;min-height:1px;padding-right:15px;padding-left:15px}@media (min-width:992px){.col-md-12{float:left}.col-md-12{width:100%}}.collapse{display:none} .nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{max-height:340px;padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:0;margin-left:0}}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}.navbar-nav.navbar-right:last-child{margin-right:-15px}}@media (min-width:768px){.navbar-right{float:right!important}}.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{display:table;content:" "}.clearfix:after,.container-fluid:after,.container:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}html{font-size:14px;overflow-y:scroll;overflow-x:hidden;-ms-overflow-style:scrollbar}@media(min-width:60em){html{font-size:16px}}body{background:#fff;color:#6a6a6a;font-family:"Open Sans",Helvetica,Arial,sans-serif;font-size:1rem;line-height:1.5;font-weight:400;padding:0;background-attachment:fixed;text-rendering:optimizeLegibility;overflow-x:hidden;transition:.5s ease all}p{line-height:1.7;margin:0 0 25px}p:last-child{margin:0}a{transition:all .3s ease 0s}a:focus,a:hover{color:#121212;outline:0;text-decoration:none}.padding-0{padding-left:0;padding-right:0}ul{font-weight:400;margin:0 0 25px 0;padding-left:18px}ul{list-style:disc}ul>li{margin:0;padding:.5rem 0;border:none}ul li:last-child{padding-bottom:0}.site-footer{background-color:#1a1a1a;margin:0;padding:0;width:100%;font-size:.938rem}.site-info{border-top:1px solid rgba(255,255,255,.1);padding:30px 0;text-align:center}.site-info p{color:#adadad;margin:0;padding:0}.navbar-custom .navbar-brand{padding:25px 10px 16px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{color:#f8504b}a{color:#f8504b}.navbar-custom{background-color:transparent;border:0;border-radius:0;z-index:1000;font-size:1rem;transition:background,padding .4s ease-in-out 0s;margin:0;min-height:100px}.navbar a{transition:color 125ms ease-in-out 0s}.navbar-custom .navbar-brand{letter-spacing:1px;font-weight:600;font-size:2rem;line-height:1.5;color:#121213;margin-left:0!important;height:auto;padding:26px 30px 26px 15px}@media (min-width:768px){.navbar-custom .navbar-brand{padding:26px 10px 26px 0}}.navbar-custom .navbar-nav li{margin:0 10px;padding:0}.navbar-custom .navbar-nav li>a{position:relative;color:#121213;font-weight:600;font-size:1rem;line-height:1.4;padding:40px 15px 40px 15px;transition:all .35s ease}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0}@media (max-width:991px){.navbar-custom .navbar-nav{letter-spacing:0;margin-top:1px}.navbar-custom .navbar-nav li{margin:0 20px;padding:0}.navbar-custom .navbar-nav li>a{color:#bbb;padding:12px 0 12px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0;color:#fff}.navbar-custom li a{border-bottom:1px solid rgba(73,71,71,.3)!important}.navbar-header{float:none}.navbar-collapse{border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.collapse{display:none!important}.navbar-custom .navbar-nav{background-color:#1a1a1a;float:none!important;margin:0!important}.navbar-custom .navbar-nav>li{float:none}.navbar-header{padding:0 130px}.navbar-collapse{padding-right:0;padding-left:0}}@media (max-width:768px){.navbar-header{padding:0 15px}.navbar-collapse{padding-right:15px;padding-left:15px}}@media (max-width:500px){.navbar-custom .navbar-brand{float:none;display:block;text-align:center;padding:25px 15px 12px 15px}}@media (min-width:992px){.navbar-custom .container-fluid{width:970px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}}@media (min-width:1200px){.navbar-custom .container-fluid{width:1170px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}} @font-face{font-family:'Open Sans';font-style:normal;font-weight:300;src:local('Open Sans Light'),local('OpenSans-Light'),url(http://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN_r8OXOhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(http://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFW50e.ttf) format('truetype')} @font-face{font-family:Roboto;font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmWUlfChc9.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfChc9.ttf) format('truetype')} </style>
</head>
<body class="">
<nav class="navbar navbar-custom" role="navigation">
<div class="container-fluid padding-0">
<div class="navbar-header">
<a class="navbar-brand" href="#">
{{ keyword }}
</a>
</div>
<div class="collapse navbar-collapse" id="custom-collapse">
<ul class="nav navbar-nav navbar-right" id="menu-menu-principale"><li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-169" id="menu-item-169"><a href="#">About</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-121" id="menu-item-121"><a href="#">Location</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-120" id="menu-item-120"><a href="#">Menu</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-119" id="menu-item-119"><a href="#">FAQ</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-122" id="menu-item-122"><a href="#">Contacts</a></li>
</ul> </div>
</div>
</nav>
<div class="clearfix"></div>
{{ text }}
<br>
{{ links }}
<footer class="site-footer">
<div class="container">
<div class="row">
<div class="col-md-12">
<div class="site-info">
<p>{{ keyword }} 2021</p></div>
</div>
</div>
</div>
</footer>
</body>
</html>";s:4:"text";s:9621:"The first participants aged 65 and older have received vaccinations in a new study assessing coadministration of a pneumococcal jab along with a COVID-19 booster shot, Pfizer announced on Monday. Two studies focused on the vaccine's usage in Israel and Qatar found that Pfizer's shot gave near total protection from the worst possible outcomes of contracting COVID-19. On November 20, 2020, Pfizer and BioNTech (the Sponsor) submitted an Emergency Use A medical worker prepares a dose of the "Comirnaty" Pfizer-BioNTech COVID-19 vaccine inside the exhibition palace transformed into a vaccination center … The study also showed the Pfizer vaccine is 97% percent effective in preventing severe COVID-19 cases, hospitalizations, and death. Setting Community testing for covid-19 in England. COVID-19 vaccines from both Pfizer and AstraZeneca are highly effective against the B.1.617.2 strain first detected in India, a study conducted by Public Health England (PHE) found. COVID-19 vaccines from both Pfizer and AstraZeneca are highly effective against the B.1.617.2 strain first detected in India, a study conducted by Public Health England (PHE) found. The aim of the study is to understand if the combination of the vaccines is safe, and the immune response after adding the pneumonia vaccine to the existing COVID … Pfizer-BioNTech COVID-19 Vaccine VRBPAC Briefing Document . The Pfizer vaccine and the Moderna vaccine use a new technology that relies on messenger RNA (mRNA) from the virus to teach the body how to protect against COVID-19.. Pfizer Inc said on Monday it has started immunizing the first patients in a new study looking at administering the company's 20-valent pneumococcal conjugate vaccine candidate following a booster dose of the Pfizer-BioNTech COVID-19 shot. BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. Pfizer vaccine may put people at higher risk for COVID variants, Israeli study shows News By Megan Redshaw, J.D. The relatively aggressive coronavirus variant first discovered in South Africa is able to "break through" Pfizer/BioNTech's Covid-19 vaccine, according to a real-world study … What. The data revealed that 75% of Moderna recipients reported side effects after getting one dose of the COVID-19 vaccine compared to 65% of the Pfizer/BioNTech recipients. The full results of a clinical trial for the Pfizer-BioNTech COVID-19 vaccine were published in the New England Journal of Medicine on Thursday, a major milestone that came as a … The full results of a clinical trial for the Pfizer-BioNTech COVID-19 vaccine were published in the New England Journal of Medicine on Thursday, a major milestone that came as a … Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study Monday, November 09, 2020 - 06:45am Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis A new COVID vaccine efficacy study from Israel has concluded that Pfizer/BioNTech's jab is up to 85% effective after the first dose. Design Test negative case-control study. The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 … Side … A study published recently and led by health experts in the United Kingdom found delaying the second dose of the Pfizer COVID-19 vaccine resulted in a stronger antibody response. Having vaccinated more people against Covid-19 per capita than any other country, Israel is in a unique position to study the effects of the first of two doses of the Pfizer/BioNTech vaccine.. Clalit, Israel’s largest health maintenance organization (HMO), looked at Covid-19 test results of 200,000 people over age 60 who were vaccinated and 200,000 people who were not. Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine … In late January, Pfizer said it had fully enrolled its Covid-19 vaccine trial in kids ages 12 to 15. The first participants aged 65 and older have received vaccinations in a new study assessing coadministration of a pneumococcal jab along with a COVID-19 booster shot, Pfizer announced on Monday. Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration … 6 . The Pfizer and BioNTech covid-19 vaccine may provide some early protection, starting 12 days after the first dose, the peer reviewed results of a phase III trial have found. The research, published in the Journal of the American … Pfizer (NYSE: PFE) stated earlier this month that it expects its COVID-19 vaccine will generate sales of close to $26 billion this year. Pfizer Inc said on Monday it began testing fully vaccinated adults over 65 in a new study that uses the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate with a third dose of the Pfizer-BioNTech COVID-19 shot.. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection Topline. The cumulative incidence of COVID-19 cases over time among placebo and vaccine recipients began to diverge by 12 days after the first dose, and 52.4% vaccine efficacy (95% confidence interval: 29.5, 68.4) was observed between dose 1 and dose 2, indicating the early onset of a partially protective effect of immunization. The latest antivaccine propaganda claims that a 2018 research paper published by researchers at Memorial Sloan-Kettering Cancer Center shows that the RNA in the Moderna and Pfizer COVID-19 vaccines can cause cancer. New study looked at the effects of the vaccine on 237 healthcare workers Executive Summary. Studying the COVID-19 Vaccine For Children In the fight against COVID-19, a vaccine is a critical part of addressing the global health crisis by decreasing rates of infection, disease and death worldwide. Pfizer has administered its first round of shots in a new study analyzing the "coadministration" of its pneumococcal vaccine candidate and a third "booster dose" of the Pfizer-BioNTech COVID-19 vaccine, the company announced on Monday.. Dear Participant, Today, Pfizer and BioNTech announced the results of the first interim analysis from our COVID-19 vaccine study. The trial will include 600 adults who will be recruited from the pivotal Phase 3 Pfizer-BioNTech COVID-19 Vaccine trial and will have received their second dose of the vaccine … A new study shows that Pfizer-BioNTech's COVID-19 vaccine is efficacious for teens, which should reassure parents and schools about reopening for vaccinated students. The Pfizer and Moderna Covid vaccines should remain highly effective against two coronavirus variants first identified in India, according to new research carried out by US scientists. A study has found that two doses of the Pfizer/BioNTech or the Astra/Zeneca vaccine protect against the COVID-19 variant first detected in India and the one first found in the United Kingdom. Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Wednesday, November 18, 2020 - 06:59am. The Pfizer-BioNTech COVID-19 Vaccine is a suspension for intramuscular injection administered as a series of two doses (0.3 mL each) 3 weeks apart. A: Pfizer-BioNTech COVID-19 Vaccine is authorized to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS … 1. Moderna And Pfizer Vaccine Studies Hampered As Placebo Recipients Get Real Shot : Shots - Health News Researchers are trying to learn more about COVID-19 vaccines from original study … Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds Download PDF Copy By Dr. Sanchari Sinha Dutta, Ph.D. May 25 2021 A large observational, real-world study from Israel estimates that the Pfizer/BioNTech COVID-19 vaccine is 46% effective at preventing infection 14 to 20 days after the first dose and 92% 7 days after the second dose, backing the results of an earlier randomized, controlled trial, according to a study today in the New England Journal of Medicine (NEJM). In early December 2020, social media users shared rumors that the “head of Pfizer research” had warned that the drug company’s new COVID-19 vaccine … COVID-19 vaccines from Moderna and Pfizer-BioNTech appear significantly less effective against the coronavirus variant first found in South Africa, a lab study has suggested. A study published recently and led by health experts in the United Kingdom found delaying the second dose of the Pfizer COVID-19 vaccine resulted in a stronger antibody response. U.S. begins study assessing allergic reactions to Pfizer and Moderna Covid vaccines Published Wed, Apr 7 2021 11:04 AM EDT Updated Wed, Apr 7 … ";s:7:"keyword";s:26:"pfizer covid vaccine study";s:5:"links";s:1316:"<a href="http://digiprint.coding.al/site/go8r5d/leica-microsystems-competitors">Leica Microsystems Competitors</a>,
<a href="http://digiprint.coding.al/site/go8r5d/house-of-balenciaga-shannon">House Of Balenciaga Shannon</a>,
<a href="http://digiprint.coding.al/site/go8r5d/continuing-medical-education-online">Continuing Medical Education Online</a>,
<a href="http://digiprint.coding.al/site/go8r5d/denitrification-definition">Denitrification Definition</a>,
<a href="http://digiprint.coding.al/site/go8r5d/bsnl-broadband-disconnection-form">Bsnl Broadband Disconnection Form</a>,
<a href="http://digiprint.coding.al/site/go8r5d/sulaymaniyah-airport-arrivals">Sulaymaniyah Airport Arrivals</a>,
<a href="http://digiprint.coding.al/site/go8r5d/cetirizine-pseudoephedrine-er-5-120-mg">Cetirizine-pseudoephedrine Er 5-120 Mg</a>,
<a href="http://digiprint.coding.al/site/go8r5d/stock-market-2020-reddit">Stock Market 2020 Reddit</a>,
<a href="http://digiprint.coding.al/site/go8r5d/is-it-safe-to-travel-to-lebanon-2020">Is It Safe To Travel To Lebanon 2020</a>,
<a href="http://digiprint.coding.al/site/go8r5d/rabiya-mateo-nationality-parents">Rabiya Mateo Nationality Parents</a>,
<a href="http://digiprint.coding.al/site/go8r5d/virtual-brokers-currency-conversion-fees">Virtual Brokers Currency Conversion Fees</a>,
";s:7:"expired";i:-1;}
Mini Shell